QoL benefits observed as early as week 2 with peginterferon alfa-2a (40KD) (pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV

被引：1

作者：

Hassanien, TI

Cooksley, WGE

Sulkowski, M

Smith, C

Marinos, G

Lai, MY

Pastore, G

Trejo-Estrada, R

Horta, A

Vale, E

Wintfeld, NS

Neary, M

Green, J

机构：

[1] Univ Calif San Diego, Ctr Liver, San Diego, CA 92103 USA

[2] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] Minn Clin Res Ctr, St Paul, MN USA

[5] Prince Wales Hosp, Randwick, NSW 2031, Australia

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] Univ Policlin, Bari, Italy

[8] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[9] Clin Diagnost Med Integral, Vila Nova De Gaia, Portugal

[10] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

来源：

关键词：

D O I：

10.1016/S0168-8278(02)80388-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

388

引用

页码：110 / 110

页数：1